Shares of Kiora Pharmaceuticals, Inc. (KPRX) are up 13% on Wednesday after the company was issued U.S. and European Patents for local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.
KPRX trades on the Nasdaq at $0.57, up 13.31% or $0.06 per share. It has traded between $0.50 and $12.28 in the past 52-week period.
The company stated that this intellectual property (IP) includes posterior non-infectious uveitis, thereby extending market exclusivity for approved indications in the U.S. and Europe.
The company stated that its KIO-104 product displayed promising results for the posterior non-infectious uveitis in a Phase 1b clinical study demonstrating decreased retinal inflammation in a dose-dependent fashion and notably improved visual acuity compared to historical controls treated with steroids or Humira.
Kiora believes that with these issued patents, it can confidently proceed with the development and commercialization of its KIO-100 family of compounds in combination with optimal delivery routes and formulations with its potential partners.
Brian Strem, President and CEO of Kiora said. "This milestone further strengthens the potential commercial position of KIO-104, as a safe and potent steroid-sparring approach. This third-generation DHODH inhibitor is a more potent molecule belonging to a validated class of FDA-approved anti-inflammatory drugs already benefitting tens of thousands of multiple sclerosis patients a year. KIO-104 could similarly provide benefit for patients in retinal inflammatory diseases like posterior non-infectious uveitis."
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.